Three-drug combination for malignant ascites from digestive cancers
Treatments studied
Part of Cancer clinical trials.
This trial tests three drugs (bevacizumab, serplulimab, and rmhTNF-NC) given together to treat fluid buildup in the belly caused by digestive system cancers. It’s for people whose ascites has not improved after standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You have a digestive system cancer (like stomach, colon, or pancreas) that has caused fluid to build up in your belly (ascites).
- You have at least a moderate amount of belly fluid that causes symptoms like bloating or shortness of breath.
- You have tried at least one prior treatment for your ascites that did not work.
- You are generally active (able to do most daily activities) and your doctor expects you to live longer than 3 months.
- You do not have serious heart problems, uncontrolled high blood pressure, or a high risk of bleeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called liposomal irinotecan, given alone or with other medications, to treat fluid buildup in the belly caused by digestive system cancers. It's for people who have already tried standard treatments without success.
This trial studies whether an immune-blocking drug placed directly into the belly cavity can help people with cancer-caused fluid buildup (malignant ascites) from stomach, pancreas, or bile-duct cancers. It may help shrink the fluid and slow the illness, but you must meet specific safety and treatment-history requirements.
This trial tests a new drug, SIM0388, for people whose cancer has spread and caused fluid buildup in the belly. It aims to see if the drug is safe and can help reduce the fluid.
This study tests a new combination of drugs and focused radiation to treat belly fluid caused by digestive system cancers. It aims to shrink tumors and reduce fluid buildup, potentially improving symptoms and quality of life.
This early-phase trial tests an experimental drug called GK02 for people with advanced cancer who have fluid buildup in the belly (malignant ascites). The drug is given directly into the belly to try to reduce the fluid and control symptoms.
This trial tests a combination of two drugs—one that helps your immune system fight cancer (immune checkpoint inhibitor) and one that strengthens bones (zoledronic acid)—given directly into the belly (intraperitoneal) to control fluid buildup caused by stomach cancer. It may help people with moderate to severe malignant ascites who have not had local belly treatments or immunotherapy recently.
Hear when a new Malignant Ascites trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.